(RTTNews) - Mural Oncology plc (MURA) on Wednesday announced that the final cash consideration payable to its shareholders upon closing of its acquisition by XOMA Royalty Corporation (XOMA) has been ...

ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural's late-stage lead candidate ...

The decision comes after Mural Oncology’s strategic review, initiated following the discontinuation of clinical development for its lead drug candidate, nemvaleukin alfa. The trial results for ...

This acquisition comes after Mural’s strategic review process, which began in April following the discontinuation of clinical development for its lead drug candidate, nemvaleukin alfa, due to ...